Oncology Xagena
AstraZeneca announced that after discussions with the FDA ( U.S. Food and Drug Administration ), the company is making a labeling change to Iressa ( Gefitinib ). Based on the FDA's assessment of cu ...
Daiichi Sankyo has announced the results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. Patients with either a history of cancer or with active c ...
Anticoagulation - For patients with active cancer, low-molecular-weight Heparin monotherapy without the transition to oral anticoagulation is preferred over Warfarin ( Coumadin ) by evidence-based gui ...
The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and veno ...
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor prognosis and survival. More recently, while new ...
